拜瑞妥主治什么病症？

(Rivaroxaban) is a drug with rivaroxaban tablets as the main component. It is a red film-coated tablet. Xarelto is a highly selective oral drug that directly inhibits factor Xa. By inhibiting factor Xa, it can interrupt the endogenous and exogenous pathways of the coagulation waterfall and inhibit the generation of thrombin and thrombosis. Today let’s take a closer look at what diseases Xarelto treats?

Xarelto is mainly used to treat venous thrombosis in adults.

Xarelto is indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Xarelto (rivaroxaban) is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

Xarelto is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack).

The four RECORD1-4 studies of Xarelto (rivaroxaban) to prevent VTE after total hip and knee replacement surgery are a series of randomized, double-blind, multi-center clinical trials. The RECORD1-2 study evaluated the safety and effectiveness of Xarelto in preventing VTE in patients undergoing elective total hip replacement surgery.

The results showed that compared with enoxaparin, Xarelto (rivaroxaban) could significantly reduce the incidence of total VTE, major VTE and symptomatic VTE, while the incidence of major bleeding events and other bleeding events was similar in the two groups. The RECORD3~4 study compared the safety and effectiveness of the above two drugs in preventing venous thromboembolism in patients after elective total knee replacement. The incidence rate of the primary endpoint event in the enoxaparin group was 18.9%, while that of Xarelto was only 9.6%. The difference between the two was statistically significant (P<0.001). The results showed that the efficacy of the Xarelto group was not inferior to traditional treatment, and the risk of bleeding was equivalent to or lower than traditional treatment. 

Xarelto (rivaroxaban) is a common anticoagulant drug that has been widely used in the prevention and treatment of hip (or knee) joint replacement surgery, deep vein thrombosis, pulmonary embolism, valvular atrial fibrillation and other diseases. It can inhibit factor

The above is the indications of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76550.html